Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...

Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. Teoxane ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $38.88, with a -1.09% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 0.16%.

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

Palvella Therapeutics (PVLA) announced results from the Phase 2 study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations were published in the Journal ...

Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN™ rapamycin ...